Gufic BioSciences Ltd

Gufic BioSciences has announced its financial results for the quarter ending December 2024, highlighting its highest quarterly net sales in five quarters at Rs 207.79 crore. However, challenges include a low operating profit to interest ratio, declining profit before tax, and reduced operating profit margin, indicating profitability concerns.

Gufic BioSciences has experienced significant trading activity, gaining 7.11% on January 31, 2025, and outperforming its sector. The stock has shown a consistent upward trend over three days, reaching an intraday high of Rs 444.8, while also surpassing the performance of the Sensex.

Gufic BioSciences experienced a notable decline in its stock price on January 13, 2025, underperforming compared to its sector. Despite being above longer-term moving averages, it fell short of shorter-term averages. The stock's recent performance contrasts with the broader market's downturn, highlighting its distinct position.

Gufic BioSciences has experienced a revision in its score following a notable increase in stock price, outperforming the sector significantly. The company has been added to MarketsMOJO's list, reflecting its strong market position and positive performance indicators. Investors are encouraged to monitor Gufic BioSciences for potential opportunities. On December 3rd, 2024, Gufic BioSciences, a smallcap pharmaceutical firm, saw its stock price rise by 7.16%, significantly exceeding sector performance. The stock traded above all key moving averages, indicating a robust upward trend. Despite a slight decline over the past month, the company has shown resilience, outperforming the Sensex by a notable margin. Investors are advised to maintain their positions as Gufic BioSciences continues to demonstrate a stable outlook in the pharmaceutical market.

On November 18, 2024, Gufic BioSciences, a smallcap pharmaceutical company, experienced a -8.27% decline in its stock price, as reported by MarketsMOJO. Despite this, the stock is still performing well in the long term, but has underperformed in comparison to the overall market. Investors should carefully consider their options before making any decisions regarding this stock.

Gufic BioSciences, a smallcap pharmaceutical company, reported a flat performance in the second quarter of fiscal year 2024-2025. The company's dividend per share has increased, but its operating profit to interest ratio is the lowest in five quarters. Investors are advised to hold their position in the company's stock, according to MarketsMOJO.

Gufic BioSciences, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on November 8th, 2024. The stock has been performing well, outperforming the sector by 3.62% and showing a consecutive gain for the last 6 days. It is currently trading higher than its moving averages, indicating a positive trend.

Gufic BioSciences, a smallcap pharmaceutical company, has seen a 90.44% increase in its stock price in the past year, outperforming the Sensex's growth. Despite a recent decrease, the stock is still trading higher than its moving averages, indicating a positive trend. The company's performance has caught the attention of investors and analysts.

Gufic BioSciences, a smallcap pharmaceutical company, has seen a significant increase in its share price, reaching an all-time high of Rs. 484 on November 7th, 2024. The stock has been performing exceptionally well, outperforming the sector by 2.53% today and consistently rising for the past 5 days. With a strong performance and trading above its moving averages, Gufic BioSciences is a company to watch in the pharmaceutical industry.

Gufic BioSciences, a smallcap pharmaceutical company, has been making headlines as its stock price reached a 52-week high and outperformed the sector and benchmark index. With consecutive gains and trading above its moving averages, the company shows a strong upward trend and positive sentiment among investors.

Gufic BioSciences, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on November 6, 2024. The company's stock has outperformed the sector by 1.5% in the last four days and is currently trading close to its 52-week high. With a strong bullish trend and impressive growth compared to the Sensex, Gufic BioSciences is a promising player in the pharmaceutical industry.

Gufic BioSciences, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on November 5th, 2024. The stock has been consistently performing well, with a 6.62% increase in returns in the last 3 days. It has also outperformed the Sensex by a significant margin, showcasing its strong performance in the market.

Gufic BioSciences, a smallcap pharmaceutical company, has gained attention in the stock market as its share price reached an all-time high of Rs. 476.5 on November 5th, 2024. With a 'Hold' recommendation from MarketsMOJO, the stock has been outperforming the sector and consistently gaining for the last 3 days. Its impressive 1-year performance and trading above moving averages make it a promising company to watch.

Gufic BioSciences, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on November 4th, 2024. The stock has outperformed its sector by 6.73% and gained 6.72% in the last two days. It is currently trading above its moving averages and has shown a remarkable 1-year performance of 74.85%. With a 'Hold' call from MarketsMOJO, Gufic BioSciences is proving to be a promising player in the pharmaceutical industry.

Gufic BioSciences, a smallcap pharmaceutical company, has been performing well in the market, with its stock price reaching an all-time high on November 4th, 2024. The stock is currently rated as 'Hold' by MarketsMOJO and has outperformed the sector by 6.92%. It has also shown consistent growth and is trading higher than its moving averages, indicating a strong uptrend.

Gufic BioSciences, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on October 17, 2024. The company has been given a 'Hold' rating by MarketsMOJO and has shown high volatility. It has also outperformed the Sensex and has a strong presence in both domestic and international markets.

Gufic BioSciences, a smallcap pharmaceutical company, has seen a surge in its share price, reaching an all-time high of Rs. 473.1 on October 17, 2024. The stock has been performing well, outperforming the sector by 6.89% and showing a consecutive gain streak for the past 8 days. With a 59.94% increase in the past year, Gufic BioSciences is showcasing strong potential and growth in the pharmaceutical industry.

Gufic BioSciences, a smallcap pharmaceutical company, saw an 8.0% rise in its stock on October 16, 2024. The stock has been performing well, with a consecutive gain for 7 days and a 17.47% increase in returns. It reached a new 52-week and all-time high, indicating strong performance and potential for growth.